Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Miraculins Inc. (Miraculins) has appointed Isabella Caniggia to its scientific advisory board. Caniggia is an internationally recognized preeclampsia researcher and physician at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in Toronto (Samuel). In addition as scientist at Samuel and associate professor of Obstetrics and Gynaecology at the University of Toronto, Caniggia is a certified medical practitioner and surgeon with full registration from the Medical Counsel of Siena.
Subscribe to our email newsletter
Widely published in scientific journals and with over 100 invited presentations, Caniggia also serves as a reviewer for a number of leading peer-reviewed scientific journals and has been the recipient of numerous academic honours, grants and awards, including a number from the respected Canadian Institute of Health Research (CIHR). Caniggia’s laboratory is at the forefront of research into the molecular signatures of preeclampsia and she is the inventor of Miraculins’ promising technology in this area.
“Dr. Caniggia’s dedication to reducing the suffering of women who develop preeclampsia, after her family was personally touched by this devastating disease, is deeply inspiring and I am very proud to have Isabella join our SAB”, said Christopher J. Moreau, president and chief executive officer of Miraculins. “Her leading research on hypoxic conditions of the placenta has advanced the field for early preeclampsia detection methods and includes the discovery of endoglin, which has consistently been the top performing biomarker for preeclampsia in a number of independent clinical studies.”
“I am pleased to join Miraculins in working towards the goal of better outcomes for women with preeclampsia and I am encouraged that our work will lead to improved early diagnostic tools so that physicians will no longer have to rely on symptoms alone to determine if a patient is at risk for developing preeclampsia”, commented Caniggia.